The Australian Nuclear Science and Technology Organisation (ANSTO) is entering into a joint venture with Cyclotek to build a new theranostics facility in Melbourne.
The facility will allow the two organizations to develop, manufacture, and supply therapeutic radiopharmaceuticals for cancer treatment, the firms said. They will build it under the auspices of a new company called Applied Molecular Therapeutics and will focus initially on lutetium-177.
